Circulating Tumor DNA To Assess Minimal Residual Disease: Versatile, but How Valuable?
- Jason R Brown 1, Guru P Sonpavde 2, Adam Calaway 3, Pedro C Barata 1
- Jason R Brown 1, Guru P Sonpavde 2, Adam Calaway 3
- 1Division of Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH, USA; Case Comprehensive Cancer Center, Cleveland, OH, USA.
- 2Department of Hematology/Oncology, AdventHealth Cancer Institute and the University of Central Florida, Orlando, FL, USA.
- 3Case Comprehensive Cancer Center, Cleveland, OH, USA; Department of Urology, University Hospitals Seidman Cancer Center, Cleveland, OH, USA.
- 0Division of Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH, USA; Case Comprehensive Cancer Center, Cleveland, OH, USA.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.

